35 results about "Histologic type" patented technology

A monoclonal antibody, 3E10, and active fragments thereof that selectively are transported in vivo to the nucleus of mammalian cells without cytotoxic effect are provided. The antibody and other molecules that bind to a variant of myosin IIb heavy chain found in the nucleus of skeletal muscle cells are useful as a non-viral delivery vector to target skeletal muscle in vivo. By contrast, in vitro the monoclonal antibody penetrates and is transported to the nucleus of multiple cell lines derived from different tissue types and can be used in screening tests to identify molecules that modulate growth of cells, such as cancer cells. Non-cytotoxic vectors for delivering a drug, polynucleotide or polypeptide selectively to skeletal muscle cells are also provided.

The present invention provides a method for detecting and differentiating disease states with high sensitivity and specificity. The method allows for a determination of whether a cellbased sample contains abnormal cells and, for certain diseases, is capable of determining the histologic type of disease present. The method detects changes in the level and pattern of expression of the molecular markers in the cell-based sample. Panel selection and validation procedures are also provided.

The present invention provides a drug delivery system wherein a "parachute" structure is coupled to a therapeutic compound. The "parachute" structure comprises hydrophilic branched molecules with a defined action diameter. The complex (a parachute structure coupled with a therapeutic compound) is either fixed at a cell membrane or delivered to a defined distance from the membrane within the cell. The membrane-anchoring / localizing effect of the parachute is achieved by hydrophilic structures linked with a branching unit of desired therapeutic compounds. Furthermore, the parachute structures can be connected by a spacer (e.g. beta-amino acids, gamma-amino butyric acid, or poly-amino acids) instead of directly binding to the therapeutic compound, so that the therapeutic compounds can be localized within the cells at a defined distance from the cell membrane. A spacer containing a breaking point can determine the time span, during which the drug exhibits its therapeutic activity. The hydrophilic residues can also carry signals for targeting the parachute-therapeutic complex to a defined tissue type. This can be mediated by an antibody which is specific for a tumor marker. Alternatively, a Biotin can be attached at C6 position of the sugar and then react with an Avidin-labeled tumor-specific antibody. The parachute function may also be achieved by other, more bulky hydrophilic structures such as oligosaccharides connected to the branching unit. Such sugar oligomers have specific attachment points to cell selectins, and therefore do not need additional molecular structures to target a specific tumor tissue. The use of the parachute structure gives the advantages of being able to localize a photosensitizer or chemotherapeutic drug at the site within a cell where it can destroy the tumor cell most effectively. This reduces the level of necessary systemic doses of the drugs, promotes drug excretion, and therefore considerably reduces side effects of the therapy.

An extrudable hydrogel composition useful for making a three-dimensional organ construct is described herein. Methods of using the same and products so made are also described. Also described herein is a multicellular organoid including at least two tumor cells or cell lines that are of the same tissue type, but are distinct from one another (e.g., distinct in morphology, growth rate, and / or or at least one mutation); and at least one type of non-cancerous (i.e., normal or differentiated) tissue cells, wherein the at least one type of non-cancerous tissue cells are of the same tissue type as the at least two tumor cells or cell lines. In some embodiments, the at least two tumor cells or cell lines and / or the non-cancerous tissue cells are labeled with and / or comprise a detectable compound, optionally so that each of the different cells can be distinguished from each other (e.g., optically and / or electrically distinguished).

Methods and apparatus for safely forming anastomoses comprise magnetic members configured to accommodate different tissue types and patients of differing size and weight. The magnetic members may comprise first and second magnetic members configured to engage each other with a force sufficient to form anastomosis while taking a sufficiently long time to allow the intestinal walls to fuse together. The first and second magnetic members can be configured to form anastomoses between both similar and different types of intestinal tissue. An elongate surgical placement instrument can be configured to engage and manipulate the first and second magnet members through the intestinal wall from outside the intestinal wall in order to place each of the magnetic members at desired locations.

The present invention relates to ligand-therapeutic agent conjugate compounds, silicon linkers for the conjugate compounds, compositions, methods for making them, and methods for the treatment of cancer using the conjugate compounds. The silicon-based linkers described herein can be used to deliver desired therapeutic agents to particular cells or tissue types targeted by the ligand.

Methods that enable one to specifically measure the metabolic product of a particular molecule in relatively few cells, e.g. primary cells, are described. The methods involve optionally preloading cells with labeled substrate (e.g. labeled by 13C, 15N, or 31P). The methods allow for easy identification of metabolites that are differentially generated in cells of different phenotypes. The new methods for unbiased multi-dimensional NMR screening and rapid and efficient analysis of the NMR screening identify differentially expressed metabolites in different cell or tissue types. Analysis of the differentially expressed metabolites can present unique druggable targets to which small molecule therapeutics can be designed.

Disclosed is a method of treating cancer in a patient comprising administering to the patient an effective amount of a diazeniumdiolated (N2O2-containing) compound or a pharmaceutically acceptable salt thereof, wherein the cancer cell has an elevated level of reactive oxygen species (ROS) and / or a decreased level of one or more of PRX1, PRX6, and OGG1, compared to a normal cell of the same tissue or tissue type. An example of a diazeniumdiolated compound is Formula (I), wherein X and Q are defined herein. Also disclosed are diazeniumdiolated compounds, pharmaceutical compositions, and methods of use including enhancing the chemotherapeutic treatment of chemotherapeutic agents and high energy radiation.

In accordance with the objects outlined above, the present invention provides methods of diagnosing individuals at risk for a disease state which results in aberrant Rad51 loci. The methods comprise determining the distribution of Rad51 foci in a first tissue type of a first individual, and then comparing the distribution to the distribution of Rad51 foci from a second normal tissue type from the first individual or a second unaffected individual. A difference in the distributions indicates that the first individual is at risk for a disease state which results in aberrant Rad51 loci. Preferred disease states include cancer and disease states associated with apoptosis.

Embodiments of the present disclosure are directed to treatment planning systems for a radiotherapy apparatus. In one implementation, a treatment planning system may include a computational processor configured to apply a set of instructions to an input data set. The input data set may include a three-dimensional dose distribution for delivery by the radiotherapy apparatus to a volume to be irradiated, a three-dimensional volume image characterizing tissue types within the volume to be irradiated, and a set of apparatus parameters which characterize the radiotherapy apparatus. The set of instructions may include a computational process configured to output a treatment plan for delivery of the dose distribution by the radiotherapy apparatus, by optimising a function representing a time-dependent response of the tissue types to an applied radiation.

Disclosed is a method of treating cancer in a patient comprising administering to the patient an effective amount of a diazeniumdiolated (N2O2-containing) compound or a pharmaceutically acceptable salt thereof, wherein the cancer cell has an elevated level of reactive oxygen species (ROS) and / or a decreased level of one or more of PRX1, PRX6, and OGG1, compared to a normal cell of the same tissue or tissue type. An example of a diazeniumdiolated compound is Formula (I), wherein X and Q are defined herein. Also disclosed are diazeniumdiolated compounds, pharmaceutical compositions, and methods of use including enhancing the chemotherapeutic treatment of chemotherapeutic agents and high energy radiation.

A system and method is provided for using ultrasound data backscattered from vascular tissue to estimate the transfer function of a catheter (including components attached thereto—e.g., IVUS console, transducer, etc.). Specifically, in accordance with a first embodiment of the present invention, a computing device is electrically connected to a catheter and used to acquire RF backscattered data from a vascular structure (e.g., a blood vessel, etc.). The backscattered ultrasound data is then used, together with an algorithm, to estimate the transfer function. The transfer function can then be used (at least in a preferred embodiment) to calculate response data for the vascular tissue (i.e., the tissue component of the backscattered ultrasound data). In a second embodiment of the present invention, an IVUS console is electrically connected to a catheter and a computing device and is used to acquire RF backscattered data from a vascular structure. The backscattered data is then transmitted to the computing device, where it is used to estimate the catheter's transfer function and to calculate response data for the vascular tissue. The response data and histology data are then used to characterize at least a portion of the vascular tissue (e.g., identify tissue type, etc.).

The invention belongs to the technical field of experiment animals and medical image processing and application, and specifically relates to an evaluation method for tumour model effective intervention based on an optical imaging technology. The method comprises: using bioluminescence and fluorescent techniques to mark tumour model cells, using optical detection instruments to directly detect activities of the marked cells of a tumour model and behaviors of marked genes, observing expression or interaction of specific cells, genes, and molecules, and meanwhile detecting a plurality of kinds of molecular events, tracking targets, and imaging and evaluating an intervening measure effect from molecular and cellular level. The method can observe growth and metastasis of tumour cells in vivo and reaction after intervention in real time. Further, the method can be used for simply, conveniently, and accurately screen out effective intervention measures or effective intervention compatibility measures for different histological pattern tumours.

The invention provides regulatory elements, as well as vectors containing the same that may be used to stimulate transcription of a gene of interest in certain tissue types. The transcription regulatory elements described herein may be operably linked to a transgene, such as acid alpha-glucosidase (GAA), so as to promote expression of the GAA transgene in a cell, such as a muscle cell, liver cell, or neuron. The transcription regulatory elements described herein may be operably linked to a therapeutic transgene and used for the treatment of various disorders, such as lysosomal storage diseases, and particularly Pompe disease.

Herein, when an electrode is used to apply an electric field in a target tissue within an anatomical volume (e.g., applying TTField to treat a tumor), the position of the electrode may be optimized by obtaining conductivity measurements in the anatomical volume and generating a 3D map of conductivity directly from the obtained conductivity or resistivity measurements without dividing the anatomical volume into tissue types. A location of the target tissue is identified within the anatomical volume, and a location for the electrode is determined based on the 3D map of conductivity and the location of the target tissue.

The present disclosure relates to a surgical tool for cutting and hemostasis of biological tissues. The surgical tool includes a hollow blade comprising a cutting implement residing within a hollow cavity configured to provide high-pressure steam through an apical surface. The cutting implement can operate independently or in cooperation with the provided high-pressure steam. The surgical tool of the present disclosure applies a directionally-controlled, high-pressure steam flow to a tissue region of interest. A control unit provides temperature-controlled steam at a flow-rate determined in accordance with tissue type and intended procedure.

The invention provides molecular markers related to the prognosis of non-small cell lung cancer and applications thereof. The present invention combines the non-small cell lung cancer (NSCLC) gene chip expression data set, uses random forest method and Cox single factor regression analysis, finds the genes whose expression level is significantly related to the patient's survival period among the candidate genes, and uses Cox multifactor for these genes Regression analysis was used to model the survival analysis, and the performance of the model was evaluated by the Kaplan Meier method and the time-dependent ROC analysis method, and a lung cancer prognosis label set of 17 genes was obtained. The length of survival and the risk of recurrence are graded for individualized treatment. This molecular marker is not affected by factors such as NSCLC tissue type, disease stage, age, gender, etc. It can be used as a tool for evaluating the prognosis of NSCLC and has universal applicability to NSCLC patients.

The invention discloses a DNA drug for treating tumors by a targeted immune system and application thereof, and relates to the technical field of biological medicines. The drug comprises effective components including an expression vector and a human immunocompetence factor gene segment loaded on the expression vector, the expression vector is a non-replication gene vector, and tissue specific promoters loaded on the expression vector are different when the expression vector is applied to treatment of tumors of different tissue types. The human immunocompetence factor is a human T cell co-activation factor, is subjected to ectopic expression on the surface of a tumor cell, and is used for targeting system immune response. After intratumoral injection administration, T cell co-activation factor ectopic high expression on tumor cell membranes of different tissue types is realized under the regulation and control of different tissue specific promoters, and T cells interact with ligands / receptors on the surfaces of T cells to activate the systematic immune response of the T cells to tumors.

Disclosed are liposomal formulations and biomimetic proteolipid nanoparticles that possess remarkable properties for targeting compounds of interest to particular mammalian cell and tissue types. Leukocyte-based biomimetic nanoparticles are disclosed that incorporate cell membrane proteins to transfer the natural tropism of leukocytes to the final delivery platform. However, tuning the protein integration can affect the in vivo behavior of these nanoparticles and alter their efficacy. Here it is shown that, while increasing the protein:lipid ratio to a maximum of 1:20 (w / w) maintained the nanoparticle's structural properties, increasing protein content resulted in improved targeting of inflamed endothelium in two different animal models. The combined use of a microfluidic, bottom-up approach and tuning of key synthesis parameter enabled the synthesis of reproducible, enhanced biomimetic nanoparticles that have the potential to improve treatment of inflammatory-based conditions through targeted nanodelivery, including particular cancers such as human breast cancer, and TNBC in particular.

The present invention is concerned with a composition and in vitro method for generating a desired cell type and / or tissue type from hair follicular stem cells. The composition and in vitro method are particularly suitable for generating an autologous desired cell type and / or tissue type. Furthermore, the composition and method are especially efficient and suitable for use in the context of cosmetic cell and / or tissue transplantation in recipient areas of a subject experiencing cell and / or tissue loss caused by, for example, a wound, scar, burn injury, tissue degeneration, and aging. The composition and in vitro method are also suitable to circumvent complications related to infections and / or immune rejection of a cosmetic cell and / or tissue implant or graft.

The present invention relates to nanostructured conjugates, more specifically to nanostructured fusion proteins suitable for the selective delivery of their conjugated therapeutic agents to specific cell and tissue types. It also relates to nanoparticles comprising such nanostructured proteins and the therapeutic uses thereof.

The present invention is concerned with a composition and in vitro method for generating a desired cell type and / or tissue type from hair follicular stem cells. The composition and in vitro method are particularly suitable for generating an autologous desired cell type and / or tissue type. Furthermore, the composition and method are especially efficient and suitable for use in the context of cosmetic cell and / or tissue transplantation in recipient areas of a subject experiencing cell and / or tissue loss caused by, for example, a wound, scar, burn injury, tissue degeneration, and aging. The composition and in vitro method are also suitable to circumvent complications related to infections and / or immune rejection of a cosmetic cell and / or tissue implant or graft.

The present invention relates to ligand-therapeutic agent conjugate compounds, silicon linkers for the conjugate compounds, compositions, methods for making them, and methods for the treatment of cancer using the conjugate compounds. The silicon-based linkers described herein can be used to deliver desired therapeutic agents to particular cells or tissue types targeted by the ligand.

The present invention relates to a composition comprising an isolated CD4+ Treg cell population, wherein the Treg cells have signatures for i) identifying that the T-cells are CD4+ regulatory Tcells, ii) identifying that the Treg cells are tissue type tropic, i.e they can migrate to the diseased tissue, iii) optionally identifying that the Treg cells are tropic with respect to the diseased tissue, i.e. they are homing cells, iv) identifying that the Treg cells are emigrant cells, i.e. they originate from the target tissue, and v) optionally identifying that the Treg cells are retained in the target tissue and optionally one or more X-signatures and / or one or more Y-signatures and one ore more Z-signatures.

The present invention relates to nanostructured conjugates, more specifically to nanostructured fusion proteins suitable for the selective delivery of their conjugated therapeutic agents to specific cell and tissue types. It also relates to nanoparticles comprising such nanostructured proteins and the therapeutic uses thereof.

A monoclonal antibody, 3E10, and active fragments thereof that selectively are transported in vivo to the nucleus of mammalian cells without cytotoxic effect are provided. The antibody and other molecules that bind to a variant of myosin IIb heavy chain found in the nucleus of skeletal muscle cells are useful as a non-viral delivery vector to target skeletal muscle in vivo. By contrast, in vitro the monoclonal antibody penetrates and is transported to the nucleus of multiple cell lines derived from different tissue types and can be used in screening tests to identify molecules that modulate growth of cells, such as cancer cells. Non-cytotoxic vectors for delivering a drug, polynucleotide or polypeptide selectively to skeletal muscle cells are also provided.